Key result
KLHL40-related myopathy kills ~60% of patients in early childhood, while muscle MRI tracks survivor progression.
Why the study?
Mild forms of KLHL40-related nemaline myopathy remain anecdotal, prompting a systematic review of reported cases and description of long-term follow-up to identify potential follow-up measurements.
Systematic Review (n=66)
Muscle MRI may serve as a useful biomarker to monitor disease progression in KLHL40-related myopathy, a condition with high early mortality.
Muscle MRI may aid monitoring of KLHL40-related myopathy progression; prospective validation required before clinical adoption.
BACKGROUND: gene are a common cause of severe or even lethal nemaline myopathy. Some cases with mild forms have been described, although the cases are still anecdotal. The aim of this paper was to systematically review the cases described in the literature and to describe a 12-year clinical and imaging follow-up in an Italian patient with KLHL40- related myopathy in order to suggest possible follow-up measurements. METHODS: homozygous mutation (c.1582G>A/p.E528K) was added and clinical and genetic data were collected. RESULTS: The most common mutation identified in our systematic review was the (c.1516A>C) followed by the (c.1582G>A). In our review, 60% percent of the patients died within the first 4 years of life. Clinical features were similar across the sample. Unfortunately, however, there is no record of the natural history data in the surviving patients. The 12-year follow-up of our patient revealed a slow improvement in her clinical course, identifying muscle MRI as the only possible marker of disease progression. CONCLUSIONS: Due to its clinical and genotype homogeneity, KLHL40-related myopathy may be a condition that would greatly benefit from the development of new gene therapies; muscle MRI could be a good biomarker to monitor disease progression.
No takes yet. Share an insight, caveat, or question.
Buchignani et al. (2024) conducted a systematic review in KLHL40-Related Nemaline Myopathy (n=66). KLHL40 mutations was evaluated on Survival and clinical features. KLHL40-related myopathy is a severe condition with 60% of patients dying within the first 4 years of life, though muscle MRI may serve as a biomarker to monitor disease progression in survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: